Comin’ in hot.

EORTC 62961 was a pretty funny trial dreamed up by the Germans in the 1990s: 341 patients with sarcoma were randomized to sandwich chemo (doxorubicin, ifosphamide, and etoposide) x 4 +/- “regional hyperthermia.” This meant the region of interest was raised to 42°C for 60 minutes concurrent with ifosfamide at each cycle. Long term results are published in JAMA Onc, and who’s laughing now? The patients who received hyperthermia and scored an absolute overall survival advantage of 10% at both 5 and 10 years.